When Genes Spark Inflammation: Unmasking the Hidden Link Between Inherited Retinal Diseases and Uveitis”

1. Overview of IRDs and Uveitis

Inherited retinal diseases (IRDs) are a genetically and phenotypically diverse group of disorders—over 250 genes are implicated—characterized by progressive photoreceptor dysfunction and vision loss. They can be rod-dominant, cone-dominant, or generalized, and may be syndromic (e.g., Usher, Bardet–Biedl) or non-syndromic (e.g., retinitis pigmentosa [RP], Leber congenital amaurosis [LCA], Stargardt disease).
While most IRDs lack curative treatments, gene therapy (e.g., RPE65 replacement) and other targeted approaches are emerging.

Uveitis—an intraocular inflammatory process—has been increasingly recognized in IRD patients. It may present as anterior, intermediate, posterior, or panuveitis, and can be accompanied by complications such as cystoid macular edema (CME) and retinal vasculitis. In some cases, uveitis precedes the diagnosis of IRD, suggesting that inflammation may be an early or even initiating feature in certain genotypes.

2. Clinical Patterns and Genetic Associations

The review compiles a large table of reported cases (Table 1 in the paper) linking specific gene variants to uveitis phenotypes.
Key patterns include:

• CRB1 mutations: Often associated with intermediate uveitis and CME, sometimes as the first manifestation before RP or cone–rod dystrophy. CRB1’s role in the external limiting membrane and blood–retina barrier may explain early inflammatory signs.
• ALPK1 mutations (ROSAH syndrome): Cause NF‑κB–mediated autoinflammation, optic nerve swelling, CME, vasculitis, and vitreous cells.
• CAPN5 mutations (ADNIV): Lead to progressive inflammatory vitreoretinopathy with CME, neovascularization, retinal detachment, and glaucoma.
• VCAN mutations (Wagner syndrome): Produce abnormal vitreous structure that may be antigenic, leading to chronic anterior/intermediate uveitis.
• Other implicated genes: RHO, RP1, USH2A, PRPF31, PRPF8, ABCA4, RS1, CHM, SAG, BBS1/BBS10, CLN3, NR2E3, and more.

The temporal relationship between uveitis and IRD varies:

• Uveitis first: Seen in CRB1, ALPK1, CAPN5, VCAN, and others.
• IRD first: Common in RP1, RHO, USH2A, and many syndromic IRDs.
• Concurrent onset: Less frequent but documented.

Here’s a focused synthesis of the Survey of Ophthalmology 2025 review’s findings on CRB1‑associated IRD, ADNIV (CAPN5), and Wagner syndrome (VCAN) in the context of IRD‑associated uveitis.

1. CRB1‑Associated IRD and Uveitis

Genetics & Function

• Gene: CRB1 (Crumbs homolog 1)
• Inheritance: Usually autosomal recessive
• Protein role: Maintains the external limiting membrane (ELM) and outer blood–retina barrier integrity.

Clinical Pattern

• Often presents with intermediate uveitis and cystoid macular edema (CME), sometimes years before overt retinal dystrophy (RP, cone–rod dystrophy, or LCA) is diagnosed.
• Other inflammatory signs: vitreous haze, optic nerve edema, multifocal choroiditis‑like lesions, retinal capillary leakage.
• Some cases show panuveitis with Coats‑like exudative vitreoretinopathy.

Mechanistic Insights

• CRB1 mutations compromise the ELM, allowing retinal antigens to escape into the vitreous and trigger inflammation.
• Animal data: Crb1 mutant mice show outer blood–retina barrier defects and even bacterial translocation from gut to retina, causing secondary degeneration.
• Human immunology: Increased activated CD4+/CD8+ T cells, altered dendritic and B‑cell subsets.

Treatment Experience

• Systemic immunosuppressants (methotrexate, mycophenolate, TNF‑α inhibitors, tocilizumab), periocular/intravitreal steroids, acetazolamide for CME.
• Variable response; CME often recurs.

2. ADNIV – Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (CAPN5)

Genetics & Function

• Gene: CAPN5 (calpain‑5)
• Inheritance: Autosomal dominant
• Protein role: Calcium‑activated cysteine protease in photoreceptors; mutations mislocalize the enzyme, altering proteolysis and immune signaling.

Clinical Pattern

• Onset: Uveitis is typically the first manifestation, often in early adulthood.
• Progressive course:
  1. Posterior/intermediate uveitis with vitritis and CME
  2. Pigmentary retinal degeneration
  3. Neovascularization (iris, retina)
  4. Vitreous hemorrhage, epiretinal membranes, retinal detachment, proliferative vitreoretinopathy
  5. Cataract, glaucoma, phthisis in late stages.

Mechanistic Insights

• CAPN5 mutations cause gain‑of‑function protease activity, triggering chronic intraocular inflammation and angiogenesis.
• Vitreous proteomics show upregulation of acute‑phase and complement cascade proteins, downregulation of synaptic signaling proteins.

Treatment Experience

• Local and systemic steroids, immunosuppressants, fluocinolone implants, anti‑VEGF agents, multiple surgeries (vitrectomy, glaucoma shunts, retinal detachment repair).
• Disease is relentlessly progressive despite therapy; inflammation control may slow but not halt degeneration.

3. Wagner Syndrome (VCAN‑Associated Vitreoretinopathy)

Genetics & Function

• Gene: VCAN (versican)
• Inheritance: Autosomal dominant
• Protein role: Extracellular matrix proteoglycan in vitreous; mutations (often splice‑site) alter vitreous structure.

Clinical Pattern

• Hallmark: Abnormal vitreous with optically empty spaces and avascular strands.
• Uveitis phenotype:
  • Usually chronic anterior uveitis without synechiae
  • Sometimes intermediate uveitis, CME, peripheral exudative retinal detachment
  • Glaucoma is a common complication.

Mechanistic Insights

• Abnormal vitreous matrix may expose normally sequestered antigens, bypassing the ELM and provoking immune response.
• Inflammation is often low‑grade but persistent.

Treatment Experience

• Topical steroids for anterior uveitis; periocular steroids for CME; glaucoma surgery when needed.
• Anatomic response to CME treatment can be good, but structural vitreoretinal changes persist.

Comparative Snapshot

3. Epidemiology

• Estimated prevalence of uveitis in RP: ~0.26% for clinically diagnosed cases, but subclinical inflammation is more common.
• Inflammatory masquerade syndromes: IRDs account for up to 31% of non‑neoplastic masquerades in some series, with long diagnostic delays.
• Subclinical vitreous cells are frequent: In one RP cohort, 61.5% of eyes had ≥1 cell in the anterior vitreous; 37.3% had ≥5 cells.

4. Inflammatory Phenotypes

• Anterior uveitis: Keratic precipitates, anterior chamber cells/flare, iris atrophy (sometimes Fuchs heterochromic uveitis–like).
• Intermediate uveitis: Vitreous cells/haze, snowballs, peripheral vascular leakage.
• Posterior uveitis: Retinal vasculitis, optic disc leakage, CME.
• Panuveitis: Diffuse inflammation involving all segments.
• CME: A common and vision‑threatening complication, often chronic and steroid‑responsive but prone to recurrence.

5. Mechanistic Insights

The review synthesizes human and animal data to explain how genetic defects in photoreceptors or supporting structures can trigger inflammation.

5.1 Universal Mechanism Hypothesis

Mutations affecting photoreceptor cilia or outer segments → defective disc shedding → release of immunogenic material → breakdown of blood–retina barrier → chronic inflammation.

5.2 Gene‑Specific Mechanisms

• CRB1: Disruption of external limiting membrane integrity → antigen leakage.
• ALPK1: Constitutive activation of NF‑κB pathway → systemic and ocular autoinflammation.
• CAPN5: Mislocalized protease activity → innate/adaptive immune dysregulation.
• VCAN: Abnormal vitreous matrix → exposure of sequestered antigens.

6. Role of Inflammation in IRD Pathogenesis

Historically, inflammation was considered secondary to degeneration. Now, evidence suggests it may actively contribute to disease progression:

• Antiretinal autoantibodies (AR‑AAbs): Elevated in many RP patients, especially those with CME.
• Cytokine/chemokine elevation: IL‑8, RANTES, MCP‑1, CXCL9/10, IL‑6, IL‑17, IL‑21, IL‑22, IL‑23 found in aqueous/vitreous and serum.
• Damage‑associated molecular patterns (DAMPs): Molecules like HMGB1, calreticulin, S100 proteins released from stressed/dying cells activate innate immunity.
• Microglia and Müller glia activation: Microglia migrate into degenerating photoreceptor layers, phagocytose stressed but viable cells, and secrete pro‑inflammatory mediators. Müller cells release DAMPs and cytokines, perpetuating inflammation.

7. Experimental Evidence

Table 3 in the paper summarizes key studies:

• Human studies: Show increased AR‑AAbs, inflammatory cytokines, and immune cell activation in IRD patients vs controls.
• Animal models:
  • rd10 mice (Pde6b mutation): Show sequential cytokine upregulation, microglial activation, photoreceptor apoptosis; antioxidants (N‑acetylcysteine) reduce damage.
  • Crb1 mutant mice: Impaired outer blood–retina barrier allows bacterial translocation from gut to retina, causing secondary degeneration.
  • Microglia depletion can worsen degeneration in some models, highlighting their dual protective/destructive roles.

8. Functional Protein Network Analysis

STRING analysis of implicated genes shows enrichment in:

• Photoreceptor inner/outer segments
• Cilia and ciliary membranes
• Neuron projections
• U4/U6×U5 tri‑snRNP complex (splicing factors) This supports the idea that structural/transport defects in photoreceptors predispose to barrier breakdown and inflammation.

9. Clinical Implications

• Diagnosis:
  • Consider IRD in atypical or treatment‑resistant uveitis, especially with retinal degeneration signs.
  • Genetic testing is now central to classification and prognosis.
• Management:
  • Standard uveitis therapies (steroids, immunosuppressants, biologics) are used, but responses vary by genotype.
  • CME often requires repeated/periocular/intravitreal steroids or systemic agents (e.g., acetazolamide, anti‑TNF, anti‑IL‑6).
  • Some genotypes (e.g., ALPK1) may benefit from targeted anti‑inflammatory pathway inhibitors in the future.
• Prognosis:
  • Chronic inflammation can accelerate photoreceptor loss; controlling it may preserve vision.
  • In some cases, inflammation is the first clue to an underlying IRD, enabling earlier intervention.

10. Future Directions

The authors emphasize:

• Precision medicine: Tailoring anti‑inflammatory therapy to the molecular defect (e.g., NF‑κB inhibitors for ALPK1, complement modulation for certain others).
• Early intervention: Treating inflammation before irreversible photoreceptor loss.
• Integrated care: Collaboration between uveitis and retina specialists, genetic counselors, and low‑vision services.
• Research gaps:
  • Causality between inflammation and degeneration.
  • Biomarkers to predict inflammatory flares.
  • Long‑term outcomes of immunomodulation in IRD.

11. Key Takeaways

• IRD‑associated uveitis is under‑recognized but clinically significant.
• Inflammation may be both a consequence and a driver of degeneration.
• Certain genes (CRB1, ALPK1, CAPN5, VCAN) have strong links to early or severe inflammatory phenotypes.
• Microglia, Müller cells, and DAMPs are central to the innate immune response in IRDs.
• Genetic diagnosis is essential for prognosis, counseling, and potential targeted therapy.
• Controlling inflammation—especially CME—can improve or stabilize vision, but requires individualized strategies.

📚 Citation: Hung JH, Jain T, Khatri A, Nguyen BTT, Nguyen CDT, Yavari N, Mobasserian A, Karaca I, Mohammadi SS, Gupta AS, Or CMC, Akhavanrezayat A, Yasar C, Saengsirinavin A, Than NTT, Anover FA, Elaraby O, El Feky D, Yoo WS, Zhang X, et al. Inherited retinal disease‑associated uveitis. Survey of Ophthalmology. 2025; Accepted/In press. doi:10.1016/j.survophthal.2025.03.011